PATENT CLAIM ANALYSIS

Application Number: 16131777
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "465000"]

Abstract:
A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

Claim (Index 31):
The mucoadhesive dosage form of  claim 29 , wherein the active pharmaceutical ingredient is retained in the small intestine of the subject for at least 6 hours.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 3.06522
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15102306', '15299535', '15248506', '15386175', '15582913']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7585785288631258
- 35 USC 102 Novelty (BERT): 0.5827973217875
- Combined Prediction Score: 0.7410004081555633
- Mean Citation Score: 330.58533
- Max Citation Score: 567.93396
- Similarity Product: 343.7479199929618

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test